


## PHARMACEUTICAL 2022

## Metacrine Inc. Rank 214 of 466





## PHARMACEUTICAL 2022

## Metacrine Inc. Rank 214 of 466

The relative strengths and weaknesses of Metacrine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Metacrine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Metacrine Inc. is the variable Net Income, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 63% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	78,740
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,760
Liabilities, Non-Current	0
Other Assets	902
Other Compr. Net Income	-6.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,128
Other Revenues	0
Property and Equipment	347
Research and Development	45,474
Selling, General and Administrative Expense	15,605

Output Variable	Value in 1000 USD
Assets	79,989
Liabilities	7,760
Expenses	61,079
Revenues	0
Stockholders Equity	72,229
Net Income	-62,207
Comprehensive Net Income	-62,210
Economic Capital Ratio	141%

